文献速递皮肤肿瘤毛发、甲与色素性疾病

基因重要吗?先天性黑素细胞痣的基因型-表型与基因型-结局关联

Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi.
PubMed 文献 · Br J Dermatol · 2019-08-09

该队列研究对134例先天性黑素细胞痣患者进行MC1R血检及156份痣活检的NRAS与BRAF热点高灵敏测序。结果发现NRAS突变占68%,BRAF突变占7%,双野生型占25%;BRAF突变多与多结节表型相关,基因型与儿童期神经系统疾病发生率无关。

要点

  • NRAS突变是各大小CMN最常见原因,在PAS>60cm的痣中尤为普遍。
  • BRAF突变罕见,但常与独特的多结节临床/组织学表型相关。
  • 基因型未改变儿童期神经系统疾病或黑素瘤的发生率。

核心结论

  • 各大小CMN最常由NRAS突变引起,BRAF为多发性CMN的罕见原因且常与多结节表型相关。
  • 本队列中基因型与儿童期神经系统疾病发生率差异无关。

研究设计与样本

  • 大型队列研究,对134例CMN患者进行MC1R血检及156份痣活检的NRAS与BRAF热点高灵敏基因分型。
  • 患者中男性40%,多发性CMN占76%,PAS>20cm者占59%。

主要发现

  • NRAS嵌合突变检出率为68%,与BRAF突变互斥,BRAF突变占7%,双野生型占25%。
  • 7例BRAF突变患者中5例有显著多结节表型,组织学不同于经典增生性结节。
  • NRAS突变在所有大小CMN中最常见,在PAS>60cm的痣中尤为普遍。
  • 双野生型患者面部特征较少见。
  • 基因型未改变先天性神经系统疾病及黑素瘤的发生率;BRAF突变多发性CMN中未见黑素瘤病例,但该基因型罕见。

关键数值与推荐

  • NRAS嵌合突变占68%,BRAF突变占7%,双野生型占25%。
  • 多发性CMN中NRAS突变占70-80%(已知背景)。

临床怎么用

  • 怀疑黑素瘤时应进行基因分型以指导治疗。
  • BRAF突变与多结节表型相关,需注意识别。

局限性

  • BRAF突变多发性CMN中未见黑素瘤病例,但该基因型罕见。
  • 当前样本量下未观察到基因型间不良结局差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genotype-phenotype studies can identify subgroups of patients with specific clinical features or differing outcomes, which can help shape management. OBJECTIVES: To characterize the frequency of different causative genotypes in congenital melanocytic naevi (CMN), and to investigate genotype-phenotype and genotype-outcome associations. METHODS: We conducted a large cohort study in which we undertook MC1R genotyping from blood, and high-sensitivity genotyping of NRAS and BRAF hotspots in 156 naevus biopsies from 134 patients with CMN [male 40%; multiple CMN 76%; projected adult size (PAS) > 20 cm, 59%]. RESULTS: Mosaic NRAS mutations were detected in 68%, mutually exclusive with BRAF mutations in 7%, with double wild-type in 25%. Two separate naevi were sequenced in five of seven patients with BRAF mutations, confirming clonality. Five of seven patients with BRAF mutations had a dramatic multinodular phenotype, with characteristic histology distinct from classical proliferative nodules. NRAS mutation was the commonest in all sizes of CMN, but was particularly common in naevi with PAS > 60 cm, implying more tolerance to that mutation early in embryogenesis. Facial features were less common in double wild-type patients. Importantly, the incidence of congenital neurological disease, and apparently of melanoma, was not altered by genotype; no cases of melanoma were seen in BRAF-mutant multiple CMN, however, this genotype is rare. CONCLUSIONS: CMN of all sizes are most commonly caused by mutations in NRAS. BRAF is confirmed as a much rarer cause of multiple CMN, and appears to be commonly associated with a multinodular phenotype. Genotype in this cohort was not associated with differences in incidence of neurological disease in childhood. However, genotyping should be undertaken in suspected melanoma, for guidance of treatment. What's already known about this topic? Multiple congenital melanocytic naevi (CMN) have been shown to be caused by NRAS mosaic mutations in 70-80% of cases, by BRAF mosaicism in one case report and by inference in some previous cases. There has been debate about genotypic association with different sizes of CMN, and no data on genotype-outcome. What does this study add? NRAS mosaicism was found in 68%, BRAF in 7% and double wild-type in 25% of cases of CMN. NRAS was the commonest mutation in all sizes of CMN, but was nearly universal in projected adult size > 60 cm. BRAF is often associated with a distinct multinodular clinical/histological phenotype. Adverse outcomes did not differ between genotypes on current numbers.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Polubothu S, McGuire N, Al-Olabi L, et al. Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi. Br J Dermatol. 2019. PMID: 31111470. doi:10.1111/bjd.18106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。